Articles tagged with Cancer Patients
Researchers discovered that loss of function of FAT1 promotes hybrid EMT phenotype, characterized by co-expression of epithelial and mesenchymal genes in tumor cells, leading to metastasis and poor clinical outcome. FAT1 mutated cancers are highly resistant to several drugs, including EGFR inhibitor.
A UK national study found that children with cancer who test positive for COVID-19 have mild infections or are asymptomatic, with no deaths reported and only 5% requiring intensive care support. The study's real-time data helped inform shielding advice for this group of patients.
The Patient Researcher Forum allows patients and researchers to learn from each other, fostering interdisciplinary collaboration. The program has a positive impact on perspectives of both parties, with patients gaining insight into the importance of cancer research and researchers becoming more patient-centered in their work.
A large retrospective study found that patients with non-small cell lung cancer who developed two immune-related side effects had improved patient survival and delayed tumor progression. The researchers identified a correlation between multisystem immune-related adverse events and improved survival outcomes.
A new study suggests that most rectal cancer patients can replace aggressive surgery with radiochemotherapy and close surveillance, with a low risk of tumor regrowth. Almost 70% of patients who underwent the 'watch and wait' protocol remained cancer-free for years, making intensive follow-up possible.
A study published in Journal of the American College of Surgeons found that financial toxicity among breast cancer patients is independently associated with worse psychological well-being. Even small improvements in financial pressure can lead to better mental well-being and higher patient satisfaction with breast reconstruction.
Researchers developed a new model to predict kidney function in cancer patients, enabling more accurate chemotherapy dosing and minimizing harm. The model takes into account various factors like age, gender, and body mass index, providing clinicians with a valuable tool for guiding treatment decisions.
A survey is being conducted to characterize marijuana use among cancer patients receiving care at MUSC Hollings Cancer Center. The study aims to explore how often patients are using marijuana, why they're using it, and their perceptions of its efficacy in managing symptoms. The findings will provide insight into the prevalence and spec...
A recent study analyzed risk factors and racial disparities among US patients with specific types of cancer who contracted COVID-19. The research found significant differences in outcomes between cancer types and racial groups.
Researchers found that adding an immune checkpoint inhibitor to standard chemotherapy for patients with early-stage breast cancer does not decrease their ability to perform daily activities. The study, based on data from the IMpassion031 trial, showed increased response rates and no significant impact on quality of life.
A new treatment approach called 'organ preservation' uses radiotherapy followed by local keyhole surgery to remove only the part of the rectum affected by cancer. Patients who received this treatment reported fewer side effects, such as diarrhoea and the need for a permanent colostomy bag, compared to those who underwent major surgery.
Researchers found non-pharmacological interventions such as fan therapy and bilevel ventilation to be effective in improving breathlessness in patients with advanced cancer. In contrast, medications like opioids had limited impact on symptom relief.
A study of 193 NYC hospital patients found that 71.6% of Black patients required hospitalization for COVID-19, compared to 46.0% of non-Blacks. Disparities were driven by a higher prevalence of comorbidities among Black patients, not cancer or treatment.
A recent study reveals unique mutation patterns in the genes PIK3CA, GNAS, SMAD3, and TSC2 among young patients with appendiceal cancer. These findings suggest potential for targeted therapies, such as alpelisib, which have already been approved for advanced breast cancer.
A new framework helps determine the exact timing of DNA mutations in cancer genomes, enabling more targeted and personalized treatments. By analyzing 22 different algorithms on nearly 300 prostate cancer samples, UCLA researchers identified biases and variability to improve treatment outcomes.
A study by researchers at Dartmouth's Geisel School of Medicine found that active surveillance can be successfully implemented in patients with low-risk thyroid cancer. The study shows that 91% of patients adhered to the prescribed ultrasonography schedule and retention rates were high, with only 4.5% choosing surgery after two years.
Researchers at Huntsman Cancer Institute have identified a potential drug combination to treat uveal melanoma by targeting genes GNAQ and GNA11. The study showed that using trametinib and hydroxychloroquine together led to more cell deaths than the drugs alone.
National mortality trends following cancer surgery improved for Black and white patients, with a 0.12% and 0.14% decline per year, respectively. However, the racial gap in mortality rates persisted, indicating a need for targeted efforts to address disparities in cancer surgery outcomes.
State crisis standards of care (CSC) guidelines in the US allocate scarce healthcare resources among cancer patients, requiring careful consideration of prioritization methods. The guidelines include provisions for blood products and palliative care, highlighting the need for nuanced decision-making in resource allocation.
Researchers analyzed data from nearly half a million cancer patients in the US between 15-39 years old to determine cancer cases in this age group. The results show a 30% rise in cancer diagnoses among adolescents and young adults, with kidney, thyroid, and gastrointestinal cancers increasing at the greatest rates.
A Memorial Sloan Kettering study is the first to link gut microbiota to changes in the human immune system. The research used over 10 years of data from more than 2,000 patients undergoing blood stem cell transplants, revealing a unique relationship between microbiota and immune cell concentrations.
A new therapy stimulating immune system response against cancer shows an acceptable safety profile when used alone or with checkpoint inhibitors. BMS-986178 demonstrates manageable adverse events and no dose-limiting toxicities, suggesting its potential as a treatment for patients with solid tumors.
The ESMO Immuno-Oncology Congress 2020 discussed the latest developments in cancer treatment, including adjuvant and neoadjuvant treatments, tumour microenvironments, and novel therapeutics. The event also examined the impact of COVID-19 on immunotherapy in cancer patients.
Researchers found that concurrent dexamethasone administration with an immune checkpoint inhibitor reduced survival in both immunosensitive and immunoresistant mouse models. In human patients, those taking dexamethasone at baseline had significantly worse overall survival compared to non-users.
A new therapeutic PD-1 cancer vaccine has been shown to be safe and effective in an animal study, activating both B- and T-cell functions to promote tumor clearance. The vaccine is targeted to block signaling pathways crucial for tumor growth and maintenance, offering a promising approach to immunotherapy.
Scientists have developed a novel approach to reprogram T cells into long-lived, highly active 'super immune cells' that can fight multiple types of cancer. This breakthrough could lead to more effective and durable anti-cancer responses with existing treatments.
African American cancer survivors in Detroit reported common social needs, including food insecurity and housing instability, which were associated with lower health-related quality of life. The study highlights the need for a social safety net to address these disparities.
Researchers at Huntsman Cancer Institute discovered that chromatin remodeling machines have a motor-like component that drives the machine along DNA, disrupting nucleosome beads. The team found cancer-causing mutations in an area of the hub regulating motor activity, leading to improper gene expression and cancer.
A study of patients with cancer who had exceptional responses to therapy has identified molecular changes in their tumors that contribute to these unexpected and long-lasting responses. The researchers used genomic characterizations to uncover genetic alterations that may help understand the mechanisms behind these rare responses.
The EA2176 study aims to enroll 205 patients in the US with inoperable advanced squamous cell anal cancer, comparing standard chemotherapy with or without nivolumab. The trial seeks to determine if adding immunotherapy will prolong progression-free survival and reduce symptoms.
Researchers found a vaccine created to prevent melanoma recurrence is about twice as effective when patients receive two immune-boosting components, Flt3L and poly-ICLC. This combination nearly doubled the vaccine's efficacy in promoting antibodies and T cells that can later fight melanoma.
A SWOG Cancer Research Network study found that the ipilimumab and nivolumab combination shrinks rare angiosarcoma tumors in 25% of patients, with a 60% response rate for those with facial or scalp lesions, offering new hope for treatment
A recent survey by the American Cancer Society found that nearly 1 in 5 cancer patients are less likely to enroll in clinical trials during the pandemic. The top reason cited is fear of COVID-19 exposure. This could lead to reduced enrollment in trials already struggling to find patients.
Recent studies have revealed that cardiovascular adverse events, such as heart failures and arrhythmias, are common in cancer patients treated with CDK 4/6 inhibitors. These agents have significantly improved survival rates for breast cancer patients but come with a risk of cardiac damage.
A clinical trial combining a personalized cancer vaccine with Pembrolizumab has reported a 50% response rate for patients with head and neck cancer, significantly higher than previous trials without the vaccine. The preliminary data, presented by Dr. Julie Bauman, is promising and suggests the treatment is safe and tolerable.
A study by UC Davis Comprehensive Cancer Center researchers found that young survivors of AML are at risk of developing late effects, including cardiovascular, endocrine, and respiratory diseases. Non-white patients and those living in deprived neighborhoods were disproportionately affected.
Researchers found that Medicaid expansion is associated with earlier stage of diagnosis, leading to decreased mortality rates for patients with newly diagnosed breast, lung, or colorectal cancer. In states with expanded Medicaid programs, mortality rates were significantly lower than in non-expansion states.
A Mayo Clinic study found that 13.5% of cancer patients had inherited genetic mutations associated with their cancer development. The discovery could lead to targeted cancer therapies and improved survival rates for patients with these high-risk mutations.
Researchers at UT Southwestern Medical Center found that patients with acute interstitial nephritis, an autoimmune reaction, respond to immune checkpoint inhibitor drugs. This finding may have broad implications for patients being treated with ICIs.
Researchers have developed a new approach to generate T-cells faster, using polarized Th17 cells that can effectively eradicate tumors in just four days. This breakthrough has immediate clinical implications, offering a potentially long-lived and effective therapy for patients with advanced solid tumors.
Researchers have developed a new treatment that induces an integrated immune response in tumors of patients with pancreatic and colorectal cancers, which are resistant to immunotherapy. The treatment, plerixafor, works by interrupting an immunosuppressive pathway, allowing critical immune cells to infiltrate the tumors.
A national multi-institutional study found that cancer patients and their medical teams benefited from sharing symptoms in real time using web- or telephone-based reporting systems. The system improved patient satisfaction, quality of life, physical function, reduced emergency room visits, and lengthened survival.
A new Northwestern Medicine study found that patients treated by highly skilled surgeons have better long-term survival after surgery for colon cancer. The study showed a 70% lower risk of dying over five years compared to patients with less skilled surgeons.
A study by Massachusetts General Hospital found that patients with significant decision conflict prior to cancer surgery are less active after surgery. The researchers used a smartphone app and sensor data to measure physical activity levels at 30, 60, and 90 days after surgery.
Researchers at VCUarts and Massey Cancer Center developed a digital life review therapy, 'VoicingHan,' which improved symptoms and spiritual well-being in patients. The project was recognized for its innovative approach to palliative care.
A survey of 1038 healthcare professionals reveals that 69% believe patients' access to standard care treatment has been compromised during the pandemic. The study also found that 42% felt at risk of poor wellbeing and 34% showed signs of burnout, but most staff reported being able to work well despite challenges.
Researchers used AI to analyze MRI brain scans of patients with glioblastoma, identifying a significant predictor of overall and progression-free survival: the amount of muscle in the temporalis muscle. Patients with higher muscle mass had improved survival rates, highlighting a potential tool for personalized treatment planning.
A new study examined recent data on African American patients with early-stage non-small cell lung cancer and found that while Black patients are now more likely to receive effective treatments, disparities persist. The use of surgery remained a significant disparity across racial groups, despite increasing utilization over time.
A recent study published in JAMA Surgery found that low muscle mass and quality are linked to greater post-operative complications, hospitalization, and mortality in patients with colon cancer following colon resection surgery. The researchers followed 1,630 patients and used preoperative CT scans to analyze body composition.
A study published in Communications Biology found that inflammation from high IL-6 levels leads to psoriasis-like dermatitis. Researchers propose targeting IL-6 as a potential approach to preventing the condition.
A new study creates a detailed portrait of the immune response in pancreatic cancer, highlighting individual differences and pointing to the need for tailored treatments. The research identifies a potential biomarker, TIGIT, that may be targeted by future therapies.
A study by American College of Surgeons found that watch-and-wait strategy is an option for select patients with stages I to III rectal cancer. The approach, which skips operation, shows similar results in terms of local regrowth and disease-specific survival rates compared to surgical treatment.
A phase II trial shows similar safety and efficacy with single- and multiple-fraction treatment for patients with limited oligometastases. The study found comparable survival rates, local control rates, and disease-free survival rates between the two treatment groups.
Scientists identified an antibody that blocks a signaling molecule in vascular system, causing tumor lymph vessels to die and preventing metastasis. This approach may lead to new ways to block the spread of tumor cells.
A study analyzing US cancer data reveals patients from rural regions and lower-income households often have advanced liver cancer at diagnosis and face higher mortality rates. This highlights the need for targeted quality improvement interventions to address healthcare disparities affecting these populations.
A new 'next generation' BRAF inhibitor, PLX8394, has shown promising results in an early patient trial for treating various types of cancer. The treatment, taken with cobicistat, resulted in a partial response in 22% of patients, including those with glioma and bowel cancer.
A Winship Cancer Institute study shows that advanced molecular imaging with fluciclovine improves disease-free survival rates for patients with recurring prostate cancer after prostatectomy. The trial found a 12% better cancer control rate at three years, persisting at four years.
A new study found that a faecal immunochemical test (FIT) is almost 100% accurate at ruling out bowel cancer in patients with suspicious symptoms. FIT has been shown to be as sensitive as colonoscopy, the current gold standard for detection of colorectal cancer.
A UCSF-CHOP study found that patients under 25 with pediatric cancer were more likely to remain on private insurance for longer durations compared to their older peers. Brief disruptions in insurance have been associated with harmful health consequences, highlighting the importance of the ACA's dependent coverage provision.
A new staging system called STAR-CAP has been developed to predict outcomes and inform treatment decisions for men with non-metastatic prostate cancer. The system, which uses patient, tumor, and outcome data from nearly 20,000 patients, has been validated and shows strong prognostic power.